Compare Fore Kopi Indonesia Tbk. (FORE) vs Organon Pharma Indonesia Tbk. (SCPI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Fore Kopi Indonesia Tbk. vs Organon Pharma Indonesia Tbk. — how do they compare? Fore Kopi Indonesia Tbk. trades at Rp775 (market cap 7.09T, 4.99M 24h volume), while Organon Pharma Indonesia Tbk. trades at Rp29,000 (market cap 104.4B). The key difference: Fore Kopi Indonesia Tbk. is far larger — about 67.9× Organon Pharma Indonesia Tbk.'s market cap. Which is the better fit depends on your goals.
| FORE | SCPI | |
|---|---|---|
Market Cap | 7.09T | 104.4B |
Volume | 4.99M | — |
Lot | 49.86K | — |
Turnover | 3.88B | — |
Average Price | 777.82 | — |
Value | 3.88B | — |
Indicative Equilibrium Price | 775 | — |
Indicative Equilibrium Volume | 1.54K | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Fore Kopi Indonesia Tbk.
PT Fore Kopi Indonesia Tbk (the Company) was established in Jakarta based on Notarial Deed No. 6 dated July 3, 2018 of Jose Dima Satria, S.H., M.Kn. The Company commenced its commercial operations in August 2018. The controlling shareholder of the Company is EVLab Fore Pte. Ltd., through its ownership in Fore Holdings Pte. Ltd.
Read more on FORE →About Organon Pharma Indonesia Tbk.
PT Merck Sharp Dohme Pharma Tbk was established within the frame work of the Foreign Capital Investment Law No. 1 year 1967 as amended by Law No. 11 year 1970 based on Notarial Deed No. 17 dated 7 March 1972 of Djojo Muljadi, S.H. The company originally incorporated as PT. Essex Indonesia, as a joint venture between Schering Corporation, a worldwide, research-based pharmaceutical enterprise headquartered in the United States, and an Indonesian businessman.
Read more on SCPI →
